Lead Product(s) : Omeprazole
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PL Developments Gains FDA Nod for Omeprazole ANDA, Completes Debt Refinancing
Details : The FDA has approved PLD's Omeprazole Magnesium Tablet, a generic equivalent to Prilosec OTC for the treatment in adults of duodenal ulcer and gastric ulcer.
Product Name : Prilosec-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Omeprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Talicia® Launched in the United Arab Emirates
Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Product Name : Talicia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2024
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.
Product Name : Talicia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Omeprazole Magnesium,Omeprazole,Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Azurity Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients...
Product Name : Konvomep
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Azurity Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Product Name : Konvomep
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Carlin Consumer Health
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.
Product Name : Zegerid
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 02, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Carlin Consumer Health
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
